Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-cancer Drug

Dow Jones06-30

Shares of Candel Therapeutics rose after the company said it was initiating a pivotal Phase 3 trial to evaluate a lung-cancer treatment.

Shares were up 8.4% to $11.23 in trading midday Tuesday. The stock has nearly doubled in value this year.

The company said Tuesday that it had engaged the clinical-research organization Parexel International to help execute the trial, which will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab for patients with metastatic, non-squamous non-small cell lung cancer whose disease has progressed despite treatment with pembrolizumab and platinum-based chemotherapy.

The trial is expected to enroll patients across 150 sites, with a primary endpoint of overall survival and secondary endpoints including safety and quality-of-life assessments, said Candel.

The drug has been granted fast-track designation by the Food and Drug Administration, the biopharmaceutical company said.

"Building on our completed Phase 2 clinical trial, we have refined the target patient population by integrating clinical and biomarker insights to maximize the likelihood of success of the Phase 3 trial," Chief Executive Officer Paul Peter Tak said.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

June 30, 2026 11:56 ET (15:56 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647568931?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 23:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647568931","market":"sg","top_or_hot":-1,"title":"Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-cancer Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Candel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after the company said it was initiating a pivotal Phase 3 trial to evaluate a lung-cancer treatment. \n</p>\n<p>\n  Shares were up 8.4% to $11.23 in trading midday Tuesday. The stock has nearly doubled in value this year. \n</p>\n<p>\n  The company said Tuesday that it had engaged the clinical-research organization Parexel International to help execute the trial, which will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab for patients with metastatic, non-squamous non-small cell lung cancer whose disease has progressed despite treatment with pembrolizumab and platinum-based chemotherapy. \n</p>\n<p>\n  The trial is expected to enroll patients across 150 sites, with a primary endpoint of overall survival and secondary endpoints including safety and quality-of-life assessments, said Candel. \n</p>\n<p>\n  The drug has been granted fast-track designation by the Food and Drug Administration, the biopharmaceutical company said. \n</p>\n<p>\n  \"Building on our completed Phase 2 clinical trial, we have refined the target patient population by integrating clinical and biomarker insights to maximize the likelihood of success of the Phase 3 trial,\" Chief Executive Officer Paul Peter Tak said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 30, 2026 11:56 ET (15:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCandel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-30 23:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Candel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after the company said it was initiating a pivotal Phase 3 trial to evaluate a lung-cancer treatment. \n</p>\n<p>\n  Shares were up 8.4% to $11.23 in trading midday Tuesday. The stock has nearly doubled in value this year. \n</p>\n<p>\n  The company said Tuesday that it had engaged the clinical-research organization Parexel International to help execute the trial, which will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab for patients with metastatic, non-squamous non-small cell lung cancer whose disease has progressed despite treatment with pembrolizumab and platinum-based chemotherapy. \n</p>\n<p>\n  The trial is expected to enroll patients across 150 sites, with a primary endpoint of overall survival and secondary endpoints including safety and quality-of-life assessments, said Candel. \n</p>\n<p>\n  The drug has been granted fast-track designation by the Food and Drug Administration, the biopharmaceutical company said. \n</p>\n<p>\n  \"Building on our completed Phase 2 clinical trial, we have refined the target patient population by integrating clinical and biomarker insights to maximize the likelihood of success of the Phase 3 trial,\" Chief Executive Officer Paul Peter Tak said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 30, 2026 11:56 ET (15:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2647568931","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647568931","pubTimestamp":1782834960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Candel Therapeutics rose after the company said it was initiating a pivotal Phase 3 trial to evaluate a lung-cancer treatment.Shares were up 8.4% to $11.23 in trading midday Tuesday. The stock has nearly doubled in value this year.The company said Tuesday that it had engaged the clinical-research organization Parexel International to help execute the trial, which will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab for patients with metastatic, non-squamous non-small cell lung cancer whose disease has progressed despite treatment with pembrolizumab and platinum-based chemotherapy.The trial is expected to enroll patients across 150 sites, with a primary endpoint of overall survival and secondary endpoints including safety and quality-of-life assessments, said Candel.The drug has been granted fast-track designation by the Food and Drug Administration, the biopharmaceutical company said.\"Building on our completed Phase 2 clinical t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","CADL":"Candel Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Candel Therapeutics启动肺癌药物3期试验后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CADL":1.5},"content_text":"Shares of Candel Therapeutics rose after the company said it was initiating a pivotal Phase 3 trial to evaluate a lung-cancer treatment. \n\n\n  Shares were up 8.4% to $11.23 in trading midday Tuesday. The stock has nearly doubled in value this year. \n\n\n  The company said Tuesday that it had engaged the clinical-research organization Parexel International to help execute the trial, which will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab for patients with metastatic, non-squamous non-small cell lung cancer whose disease has progressed despite treatment with pembrolizumab and platinum-based chemotherapy. \n\n\n  The trial is expected to enroll patients across 150 sites, with a primary endpoint of overall survival and secondary endpoints including safety and quality-of-life assessments, said Candel. \n\n\n  The drug has been granted fast-track designation by the Food and Drug Administration, the biopharmaceutical company said. \n\n\n  \"Building on our completed Phase 2 clinical trial, we have refined the target patient population by integrating clinical and biomarker insights to maximize the likelihood of success of the Phase 3 trial,\" Chief Executive Officer Paul Peter Tak said. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 30, 2026 11:56 ET (15:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.1","shortVersion":"4.45.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647568931","isCrawlerRequest":true}